ARTELO BIOSCIENCES, INC. 8-K

What Happened

• Artelo Biosciences, Inc. (ARTL) announced in an 8‑K that on April 6, 2026 Nasdaq confirmed the company has regained compliance with Listing Rule 5550(b)(1) (stockholders’ equity of at least $2.5 million) and Listing Rule 5620(a) (holding an annual shareholders’ meeting). The Nasdaq Hearings Panel had previously granted the company an exception on February 2, 2026 to cure those deficiencies.

Key Details

• Nasdaq confirmed compliance by letter dated April 6, 2026; Artelo issued a press release on April 7, 2026.
• The equity rule at issue requires at least $2.5 million in stockholders’ equity (Nasdaq Listing Rule 5550(b)(1)).
• Under Nasdaq Listing Rule 5815(d)(4)(B), Artelo is subject to a Mandatory Panel Monitor through April 6, 2027.
• If, during that monitoring year, Nasdaq staff again finds Artelo out of compliance with the equity rule that was covered by the exception, Nasdaq will issue a Delist Determination Letter without allowing a new compliance plan or cure period; Artelo could request a hearing and potentially face delisting.

Why It Matters

• For investors, the filing confirms ARTL’s Nasdaq listing status has been restored for now, which preserves liquidity and continued trading on Nasdaq. However, the company is on heightened oversight for one year: any repeat shortfall in the specific equity requirement could trigger a faster delisting process without the usual opportunity for an extended cure period. This is a material governance and listing‑risk update to monitor alongside the company’s financial results and capital position.